Literature DB >> 21837790

Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males.

Sara L Bissett1, Rebecca Howell-Jones, Craig Swift, Natasha De Silva, Leon Biscornet, John V Parry, Nicholas A Saunders, Mayura Nathan, Kate Soldan, Anne Szarewski, Jack Cuzick, Simon Beddows.   

Abstract

The ability to detect type-specific high risk HPV (HR-HPV) infections in samples from females and males is important for monitoring the epidemiology of HPV and the impact of vaccination. Type-specific detection concordance between paired urine and genital samples from females (n = 264) undergoing routine colposcopy and males (n = 88) attending a genito-urinary medicine clinic was evaluated using an in-house genotyping assay. The overall inter-rater agreement (κ) was 0.781 for female pairs and 0.346 for male pairs. Female urine had sensitivity for detection of HPV16/18 and HR-HPV of 75% and 84%, respectively, while male urine had sensitivities of 13% and 28%, respectively. Genital samples had a higher HPV DNA copy number than urine although a small proportion (10%) of urine samples had a higher copy number than the corresponding genital sample. The proportion of females with normal cytology positive for HPV16/18 was 19%, increasing to 57% in moderate or severely dyskaryotic samples. The same trend was seen in the corresponding urine (19-43%) compounded by the reduced sensitivity of this sample type. The HPV16 viral load in female genital samples, but not in urine, was weakly associated with cervical disease stage. Despite reduced sensitivity, urine appears to be an appropriate surrogate sample for type-specific HPV detection in females for epidemiological objectives. The lower sensitivity and lack of association between viral load and disease stage in urine suggest that urine may not be useful for clinical management of HPV infection. The utility of urine for type-specific detection in males is less certain.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21837790     DOI: 10.1002/jmv.22167

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  22 in total

1.  Detection of human papillomavirus type 18 E7 oncoprotein in cervical smears: a feasibility study.

Authors:  Daniela Ehehalt; Barbara Lener; Haymo Pircher; Kerstin Dreier; Heiko Pfister; Andreas M Kaufmann; Sergio Frangini; Sigrun Ressler; Elisabeth Müller-Holzner; Markus Schmitt; Daniela Höfler; Ursula Rostek; Andreas Kaiser; Andreas Widschwendter; Werner Zwerschke; Pidder Jansen-Dürr
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

2.  The role of monogamy and duration of heterosexual relationships in human papillomavirus transmission.

Authors:  Alan G Nyitray; Hui-Yi Lin; William J Fulp; Mihyun Chang; Lynette Menezes; Beibei Lu; Martha Abrahamsen; Mary Papenfuss; Christine Gage; Claudia M Galindo; Anna R Giuliano
Journal:  J Infect Dis       Date:  2013-11-18       Impact factor: 5.226

3.  Comparison of human papillomavirus detections in urine, vulvar, and cervical samples from women attending a colposcopy clinic.

Authors:  Vikrant V Sahasrabuddhe; Patti E Gravitt; S Terence Dunn; David Brown; Richard A Allen; Yolanda J Eby; Katie Smith; Rosemary E Zuna; Roy R Zhang; Michael A Gold; Mark Schiffman; Joan L Walker; Philip E Castle; Nicolas Wentzensen
Journal:  J Clin Microbiol       Date:  2013-11-06       Impact factor: 5.948

4.  High-Risk Human Papillomavirus (HPV) Infection and Cervical Cancer Prevention in Britain: Evidence of Differential Uptake of Interventions from a Probability Survey.

Authors:  Clare Tanton; Kate Soldan; Simon Beddows; Catherine H Mercer; Jo Waller; Nigel Field; Soazig Clifton; Andrew J Copas; Kavita Panwar; Precious Manyenga; Filomeno da Silva; Kaye Wellings; Catherine A Ison; Anne M Johnson; Pam Sonnenberg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-03-03       Impact factor: 4.254

5.  Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain.

Authors:  Anne M Johnson; Catherine H Mercer; Simon Beddows; Natasha de Silva; Sarika Desai; Rebecca Howell-Jones; Caroline Carder; Pam Sonnenberg; Kevin A Fenton; Catherine Lowndes; Kate Soldan
Journal:  Sex Transm Infect       Date:  2012-01-17       Impact factor: 3.519

6.  Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies.

Authors:  E M King; R Gilson; S Beddows; K Soldan; K Panwar; C Young; P Prah; M Jit; W J Edmunds; P Sonnenberg
Journal:  Br J Cancer       Date:  2015-03-19       Impact factor: 7.640

7.  Oral human papillomavirus (HPV) infection in men who have sex with men: prevalence and lack of anogenital concordance.

Authors:  Eleanor M King; Richard Gilson; Simon Beddows; Kate Soldan; Kavita Panwar; Carmel Young; Mark Jit; W John Edmunds; Pam Sonnenberg
Journal:  Sex Transm Infect       Date:  2015-04-17       Impact factor: 3.519

8.  Monitoring human papillomavirus prevalence in urine samples: a review.

Authors:  Espen Enerly; Cecilia Olofsson; Mari Nygård
Journal:  Clin Epidemiol       Date:  2013-03-12       Impact factor: 4.790

9.  Patterns of human papillomavirus types in multiple infections: an analysis in women and men of the high throughput human papillomavirus monitoring study.

Authors:  Salvatore Vaccarella; Anna Söderlund-Strand; Silvia Franceschi; Martyn Plummer; Joakim Dillner
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

10.  Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal).

Authors:  Pam Sonnenberg; Soazig Clifton; Simon Beddows; Nigel Field; Kate Soldan; Clare Tanton; Catherine H Mercer; Filomeno Coelho da Silva; Sarah Alexander; Andrew J Copas; Andrew Phelps; Bob Erens; Philip Prah; Wendy Macdowall; Kaye Wellings; Catherine A Ison; Anne M Johnson
Journal:  Lancet       Date:  2013-11-26       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.